Jaguar Gene Therapy lands two investors

LAKE FOREST - Jaguar Gene Therapy, a biotechnology company exploring breakthroughs in gene therapies, said Samsung Ventures and JDRF T1D Fund have invested in the company.

Samsung Ventures is a technology investment corporation while the JDRF T1D Fund is a venture philanthropy fund devoted to finding the best cure-oriented therapies for Type 1 diabetes.

Financial terms of the investments were not released.

Jaguar Gene Therapy said it will use the new investments, together with its existing cash resources, to expand its preclinical pipeline of gene therapy programs targeting Type 1 galactosemia, genetic causes of autism spectrum disorder, Phelan-McDermid syndrome and other severe neurodevelopmental disorders.

"We are excited to add such visionary strategic investors to our existing top-tier biotech investor base," said Joe Nolan, chief executive officer of Jaguar Gene Therapy.